Sicurezza ed efficacia delle terapie per il carcinoma prostatico metastatico resistente alla castrazione (mCRPC)
4 agosto 2026 aggiornato da: Amgen
Un protocollo principale che valuta la sicurezza e l'efficacia delle terapie per il cancro alla prostata metastatico resistente alla castrazione (mCRPC)
Questo è un protocollo principale progettato per valutare la sicurezza e l'efficacia delle terapie sperimentali nei partecipanti con carcinoma prostatico metastatico resistente alla castrazione (mCRPC).
Panoramica dello studio
Stato
Stato
Terminato
Condizioni
Condizioni
Intervento / Trattamento
Intervento / Trattamento
Descrizione dettagliata
Questo è un protocollo master progettato per valutare la sicurezza, la tollerabilità e la dose massima tollerata (MTD) o la dose raccomandata di fase 2 (RP2D) e l'efficacia di Acapatamab, in combinazione con enzalutamide, abiraterone o l'inibitore PD1 AMG 404, AMG 404 in monoterapia , così come la monoterapia con Acapatamab, nei partecipanti con carcinoma prostatico metastatico resistente alla castrazione (mCRPC).
Tipo di studio
Tipo di studio
Interventistico
Iscrizione (Effettivo)
Iscrizione
55
Fase
Fase
- Fase 2
- Fase 1
Contatti e Sedi
Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.
Luoghi di studio
-
-
New South Wales
-
Darlinghurst, New South Wales, Australia, 2010
- St Vincents Hospital Sydney
-
-
-
-
-
København Ø, Danimarca, 2100
- Rigshospitalet
-
-
-
-
-
Sutton, Regno Unito, SM2 5PT
- Royal Marsden Hospital
-
-
-
-
Navarre
-
Pamplona, Navarre, Spagna, 31008
- Clinica Universidad de Navarra
-
-
-
-
Alabama
-
Birmingham, Alabama, Stati Uniti, 35294
- University of Alabama at Birmingham
-
-
California
-
Orange, California, Stati Uniti, 92868
- University of California at Irvine Medical Center
-
San Francisco, California, Stati Uniti, 94158
- University of California San Francisco Mission Bay Campus
-
-
Illinois
-
Chicago, Illinois, Stati Uniti, 60637
- University of Chicago
-
-
Kentucky
-
Louisville, Kentucky, Stati Uniti, 40207
- Norton Cancer Institute
-
-
Texas
-
Dallas, Texas, Stati Uniti, 75390
- University of Texas Southwestern Medical Center
-
Houston, Texas, Stati Uniti, 77030
- University of Texas MD Anderson Cancer Center
-
-
-
-
-
Lund, Svezia, 221 85
- Skånes universitetssjukhus
-
Stockholm, Svezia, 171 76
- Karolinska Universitetssjukhuset Solna
-
Uppsala, Svezia, 75185
- Akademiska Sjukhuset
-
-
Criteri di partecipazione
I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.
Criteri di ammissibilità
Criteri di ammissibilità
Età idonea allo studio
Da 18 anni a 99 anni (Adulto, Adulto più anziano)
Accetta volontari sani
No
Descrizione
Tutte le parti
Criterio di inclusione:
- ≥ 18 anni di età (o età adulta legale all'interno del paese)
- - Il soggetto ha fornito il consenso informato prima dell'inizio di qualsiasi attività/procedura specifica dello studio
- Soggetti con mCRPC con adenocarcinoma della prostata confermato istologicamente o citologicamente
- I soggetti devono essere stati sottoposti a orchiectomia bilaterale o devono essere in terapia di deprivazione androgenica continua con un agonista o antagonista dell'ormone di rilascio delle gonadotropine (testosterone ≤ 50 ng/dL (o 1,7 nmol/L))
Criteri di esclusione:
- Metastasi del sistema nervoso centrale (SNC) o malattia leptomeningea
- Storia o presenza di patologia del SNC clinicamente rilevante
- Storia confermata o malattia autoimmune in atto o altre malattie che richiedono una terapia immunosoppressiva permanente
- Infarto del miocardio, ipertensione incontrollata, angina instabile, aritmia cardiaca che richiede farmaci e/o insufficienza cardiaca congestizia sintomatica (New York Heart Association > classe II) entro 12 mesi
- Precedente trattamento con un taxano per mCRPC
- Chirurgia maggiore e/o radioterapia entro 4 settimane
Anamnesi o evidenza di infezione da coronavirus 2 (SARS-CoV-2) della sindrome respiratoria acuta grave, a meno che non sia stato concordato con il monitor medico e soddisfi i seguenti criteri:
- Test negativo per SARS-CoV-2 RNA mediante reazione a catena della polimerasi in tempo reale (RT-PCR) entro 72 ore dalla prima dose di Acapatamab (o AMG 404 nella Parte 3)
- Nessun sintomo acuto della malattia COVID-19 nei 10 giorni precedenti la prima dose di Acapatamab (o AMG 404 nella Parte 3) (contato dal giorno del test positivo per i soggetti asintomatici)
Esperienza di studio clinico precedente/concorrente
- Attualmente in trattamento in un altro dispositivo sperimentale o studio farmacologico, o meno di 4 settimane dalla fine del trattamento in un altro dispositivo sperimentale o studio farmacologico. Altre procedure sperimentali durante la partecipazione a questo studio sono escluse ad eccezione delle scansioni sperimentali.
Solo sottoprotocollo A:
Criterio di inclusione
• Soggetti che intendono ricevere enzalutamide per la prima volta per mCRPC
Criteri di esclusione
- Uso di forti inibitori del CYP2C8 o forti induttori del CYP3A4
- Uso di farmaci con indice terapeutico ristretto che sono substrati di CYP3A4, CYP2C9 o CYP2C19
Solo sottoprotocollo B:
Criterio di inclusione
- Soggetti che intendono ricevere abiraterone per la prima volta per mCRPC Criteri di esclusione
- Compromissione epatica moderata e grave al basale (Classe B e C di Child-Pugh)
- Presenza di ipertensione incontrollata, ipokaliemia o ritenzione idrica
- Storia o presenza di insufficienza surrenalica
- Uso di farmaci concomitanti che sono substrati sensibili per CYP2D6 con un indice terapeutico ristretto
- Uso di forti induttori del CYP3A4
Solo sottoprotocollo C:
Criterio di inclusione
- Soggetti refrattari a una nuova terapia antiandrogena. I soggetti devono non essere idonei o rifiutare la terapia con taxani.
- Evidenza di malattia progressiva, definita come 1 o più criteri PCWG3: livello di PSA >/=1 ng/mL che è aumentato in almeno 2 occasioni consecutive a distanza di almeno 1 settimana, progressione linfonodale o viscerale come definita da RECIST 1.1 con modifiche PCGW3, e/o comparsa di 2 o più nuove lesioni alla scintigrafia ossea Criteri di esclusione
- Anamnesi o evidenza di malattia polmonare interstiziale o polmonite attiva non infettiva
- Soggetti trattati con un precedente inibitore PD-1 o PD-L1 che hanno manifestato un evento avverso immuno-correlato di grado 3 o superiore prima del primo giorno di somministrazione della dose
Solo sottoprotocollo D:
Criterio di inclusione
- I soggetti possono aver ricevuto nuove terapie ormonali (NHT; p. es., abiraterone, enzalutamide, apalutamide o darolutamide) per il cancro alla prostata, ma non più di 1 NHT per il cancro alla prostata metastatico
- Non idoneo o rifiuto della terapia con taxani
Piano di studio
Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione sequenziale
- Mascheramento: Nessuno (etichetta aperta)
Numero di armi
11
Armi e interventi
Gruppo di partecipanti / ArmGruppo di partecipanti / Arm |
Intervento / TrattamentoIntervento / Trattamento |
|---|---|
|
Sperimentale: Acapatamab ed Enzalutamide: Esplorazione della dose
La parte di esplorazione della dose dello studio stimerà la MTD/dose di fase 2 raccomandata (RP2D) di Acapatamab in combinazione con enzalutamide.
|
Acapatamab verrà somministrato come infusione endovenosa (IV).
Altri nomi:
Enzalutamide sarà somministrato per via orale.
Altri nomi:
|
|
Sperimentale: Acapatamab ed Enzalutamide: espansione della dose
Dopo l'esplorazione della dose, sarà condotta un'espansione della dose per confermare la sicurezza e la tollerabilità della dose selezionata e per valutare ulteriormente l'efficacia di Acapatamab in combinazione con enzalutamide.
|
Acapatamab verrà somministrato come infusione endovenosa (IV).
Altri nomi:
Enzalutamide sarà somministrato per via orale.
Altri nomi:
|
|
Sperimentale: Acapatamab e Abiraterone: Esplorazione della dose
La parte di esplorazione della dose dello studio stimerà la MTD/dose raccomandata di fase 2 (RP2D) di Acapatamab in combinazione con abiraterone.
|
Acapatamab verrà somministrato come infusione endovenosa (IV).
Altri nomi:
Abiraterone verrà somministrato per via orale.
Altri nomi:
|
|
Sperimentale: Acapatamab e Abiraterone: espansione della dose
Dopo l'esplorazione della dose, sarà condotta un'espansione della dose per confermare la sicurezza e la tollerabilità della dose selezionata e per valutare ulteriormente l'efficacia di Acapatamab in combinazione con abiraterone.
|
Acapatamab verrà somministrato come infusione endovenosa (IV).
Altri nomi:
Abiraterone verrà somministrato per via orale.
Altri nomi:
|
|
Sperimentale: Acapatamab e AMG 404: Esplorazione della dose
La parte di esplorazione della dose dello studio stimerà l'MTD/RP2D di Acapatamab in combinazione con AMG 404.
|
Acapatamab verrà somministrato come infusione endovenosa (IV).
Altri nomi:
AMG 404 sarà somministrato come infusione endovenosa (IV).
Altri nomi:
|
|
Sperimentale: Acapatamab e AMG 404: espansione della dose
Dopo l'esplorazione della dose, verrà condotta un'espansione della dose per confermare la sicurezza e la tollerabilità della dose selezionata e per valutare ulteriormente l'efficacia di Acapatamab in combinazione con AMG 404.
|
Acapatamab verrà somministrato come infusione endovenosa (IV).
Altri nomi:
AMG 404 sarà somministrato come infusione endovenosa (IV).
Altri nomi:
|
|
Comparatore attivo: AMG 404 Monoterapia
La monoterapia con AMG 404 è stata condotta per valutare l'attività antitumorale preliminare dell'inibizione del PD-1 nella popolazione mCRPC.
|
AMG 404 sarà somministrato come infusione endovenosa (IV).
Altri nomi:
|
|
Sperimentale: Acapatamab ed Enzalutamide: coorte di espansione della dose in Asia
Dopo l'esplorazione della dose, l'espansione della dose sarà condotta nella coorte asiatica alla combinazione MTD/RP2D determinata nell'esplorazione della dose per confermare la sicurezza, la tollerabilità e la farmacocinetica di Acapatamab in combinazione con enzalutamide per i soggetti in Asia.
|
Acapatamab verrà somministrato come infusione endovenosa (IV).
Altri nomi:
Enzalutamide sarà somministrato per via orale.
Altri nomi:
|
|
Sperimentale: Acapatamab e Abiraterone: coorte di espansione della dose in Asia
Dopo l'esplorazione della dose, l'espansione della dose sarà condotta nella coorte asiatica alla combinazione MTD/RP2D determinata nell'esplorazione della dose per confermare la sicurezza, la tollerabilità e la farmacocinetica di Acapatamab in combinazione con abiraterone per i soggetti in Asia.
|
Acapatamab verrà somministrato come infusione endovenosa (IV).
Altri nomi:
Abiraterone verrà somministrato per via orale.
Altri nomi:
|
|
Sperimentale: Acapatamab e AMG 404: Dose Expansion Asia Cohort
Dopo l'esplorazione della dose, l'espansione della dose sarà condotta nella coorte asiatica alla combinazione MTD/RP2D determinata nell'esplorazione della dose per confermare la sicurezza, la tollerabilità e la farmacocinetica di Acapatamab in combinazione con AMG 404 per i soggetti in Asia.
|
Acapatamab verrà somministrato come infusione endovenosa (IV).
Altri nomi:
AMG 404 sarà somministrato come infusione endovenosa (IV).
Altri nomi:
|
|
Sperimentale: Monoterapia con acapatamab
La monoterapia con Acapatamab è stata condotta per valutare la sicurezza, la tollerabilità, la farmacocinetica (PK), la farmacodinamica e l'efficacia di Acapatamab nei soggetti con mCRPC.
|
Acapatamab verrà somministrato come infusione endovenosa (IV).
Altri nomi:
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Subprotocols A, B and C (Parts 1 and 2): Number of Participants Who Experienced a Dose-limiting Toxicity (DLT)
Lasso di tempo: Cycle 1: Day 1 to Day 28 (28-day cycle)
|
DLTs were defined as any adverse event (AE) (per Common Terminology Criteria for Adverse Events (CTCAE) v5: Grade 5=Death, Grade 4=Life-threatening, Grade 3=Moderate) occurring within 28 days of the first AMG 160 dose, possibly related to the treatment, including:
The complete list of DLTs are described in the protocol |
Cycle 1: Day 1 to Day 28 (28-day cycle)
|
|
Subprotocols A, B and C (Parts 1 and 2): Number of Participants Who Experienced Treatment-emergent Adverse Events (TEAEs) and Treatment-related AEs
Lasso di tempo: From first dose of acapatamab/AMG 404 to the first of 30 days after last dose of acapatamab/AMG404, end of trial date or the initiation of a new anticancer therapy; median (min, max) duration was 4.665 (0.33, 25.17) months
|
A TEAE was defined as any untoward medical occurrence in a clinical trial participant irrespective of a causal relationship with the trial treatment that started on or after first dose of investigational product (AMG 160 or AMG 404 for Part 1 and 2; AMG 404 for Part 3). A treatment-related TEAE was defined as a TEAE that had a reasonable possibility of being caused by acapatamab, or AMG 404 (subprotocol C, parts 1 and 2 only). Clinically significant changes from baseline in vital signs and clinical laboratory tests were also recorded as TEAEs. |
From first dose of acapatamab/AMG 404 to the first of 30 days after last dose of acapatamab/AMG404, end of trial date or the initiation of a new anticancer therapy; median (min, max) duration was 4.665 (0.33, 25.17) months
|
|
Subprotocol D: Number of Participants Who Experienced TEAEs and Treatment-related AEs
Lasso di tempo: From first dose of acapatamab to the first of 30 days after last dose of acapatamab, end of trial date or the initiation of a new anticancer therapy, whichever is earlier; median (min, max) duration was 4.665 (0.33, 25.17) months
|
A TEAE was defined as any untoward medical occurrence in a clinical trial participant irrespective of a causal relationship with the trial treatment that started after the first dose of acapatamab. A treatment-related TEAE was defined as a TEAE that had a reasonable possibility of being caused by acapatamab. Clinically significant changes from baseline in vital signs and clinical laboratory tests were also recorded as TEAEs. |
From first dose of acapatamab to the first of 30 days after last dose of acapatamab, end of trial date or the initiation of a new anticancer therapy, whichever is earlier; median (min, max) duration was 4.665 (0.33, 25.17) months
|
|
Subprotocol C, Part 3: Objective Response Rate (ORR)
Lasso di tempo: From Cycle 1 Day 1 until progression, start of new anticancer therapy, or end of trial median (min, max) duration was 6.14 (0.14, 105.14) weeks
|
Objective Response is defined as a complete response (CR) or partial response (PR) per RECIST 1.1, confirmed by a repeat assessment at least 4 weeks later.
Participants who did not experience a confirmed CR or PR, or did not have any follow-up tumor assessments were regarded as non-responders.
|
From Cycle 1 Day 1 until progression, start of new anticancer therapy, or end of trial median (min, max) duration was 6.14 (0.14, 105.14) weeks
|
|
Subprotocol C, Part 3: Percentage of Participants Who Experienced a Circulating Tumor Cell 0 (CTC0) Response
Lasso di tempo: Cycle 1 Day 1 to 14 days post-last dose of AMG 404 (each cycle was 28 days, maximum duration of AMG 404 treatment was 105.1 weeks)
|
CTC0 response was defined as CTC0 (reduction of CTCs > 0 to 0 at any post-baseline measurement).
The baseline was defined as the last non-missing value on or prior to the pre-dose of AMG 404 assessments on Cycle 1 Day 1.
|
Cycle 1 Day 1 to 14 days post-last dose of AMG 404 (each cycle was 28 days, maximum duration of AMG 404 treatment was 105.1 weeks)
|
|
Subprotocol C, Part 3: Percentage of Participants Who Experienced a CTC Conversion Response
Lasso di tempo: Cycle 1 Day 1 to 14 days post-last dose of AMG 404 (each cycle was 28 days, maximum duration of AMG 404 treatment was 105.1 weeks)
|
CTC conversion response was defined as ≥ 5 CTCs/7.5 mL blood at baseline that converted to ≤ 4 CTCs/7.5 mL blood at any post-baseline measurement.
The baseline was defined as the last non-missing value on or prior to the pre-dose assessments of AMG 404 on Cycle 1 Day 1.
|
Cycle 1 Day 1 to 14 days post-last dose of AMG 404 (each cycle was 28 days, maximum duration of AMG 404 treatment was 105.1 weeks)
|
|
Subprotocol C, Part 3: Percentage of Participants Who Experienced a Prostate Specific Antigen (PSA) Response
Lasso di tempo: Cycle 1 Day 1 to 5 months post-last dose of AMG 404 (each cycle was 28 days, maximum duration of AMG 404 treatment was 105.1 weeks)
|
A PSA response was defined as the below and must have been confirmed by a second consecutive value 3 weeks later:
The baseline was defined as the last non-missing value on or prior to the pre-dose of AMG 404 assessments on Cycle 1 Day 1. |
Cycle 1 Day 1 to 5 months post-last dose of AMG 404 (each cycle was 28 days, maximum duration of AMG 404 treatment was 105.1 weeks)
|
Misure di risultato secondarie
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Subprotocols A. B, C (Parts 1 and 2) and D: ORR
Lasso di tempo: From Cycle 1 Day 1 until progression, start of new anticancer therapy, or until end of trial (each cycle was 28 days, maximum duration of acapatamab treatment was 98.43 weeks/AMG 404 treatment was 105.14 weeks)
|
Objective Response is defined as a CR or PR per RECIST 1.1, confirmed by a repeat assessment at least 4 weeks later.
Participants who did not experience a confirmed CR or PR, or did not have any follow-up tumor assessments were regarded as non-responders.
|
From Cycle 1 Day 1 until progression, start of new anticancer therapy, or until end of trial (each cycle was 28 days, maximum duration of acapatamab treatment was 98.43 weeks/AMG 404 treatment was 105.14 weeks)
|
|
Subprotocols A, B, C (Parts 1 and 2) and D: Percentage of Participants Who Experienced a CTC0 Response
Lasso di tempo: From Cycle 1 Day 1 until progression, start of new anticancer therapy, or until end of trial (each cycle was 28 days, maximum duration of acapatamab treatment was 98.43 weeks/AMG 404 treatment was 105.14 weeks)
|
CTC0 response was defined as CTC0 (reduction of CTCs > 0 to 0 at any post-baseline measurement).
The baseline was defined as the last non-missing value on or prior to the pre-dose of acapatamab assessments on Cycle 1 Day 1 > 0.
|
From Cycle 1 Day 1 until progression, start of new anticancer therapy, or until end of trial (each cycle was 28 days, maximum duration of acapatamab treatment was 98.43 weeks/AMG 404 treatment was 105.14 weeks)
|
|
Subprotocols A, B, C (Parts 1 and 2) and D: Percentage of Participants Who Experienced a CTC Conversion Response
Lasso di tempo: From Cycle 1 Day 1 until progression, start of new anticancer therapy, or until end of trial (each cycle was 28 days, maximum duration of acapatamab treatment was 98.43 weeks/AMG 404 treatment was 105.14 weeks)
|
CTC conversion response was defined as ≥ 5 CTCs/7.5 mL blood at baseline that converted to ≤ 4 CTCs/7.5 mL blood at any post-baseline measurement.
The baseline was defined as the last non-missing value on or prior to the pre-dose of acapatamab assessments on Cycle 1 Day 1.
|
From Cycle 1 Day 1 until progression, start of new anticancer therapy, or until end of trial (each cycle was 28 days, maximum duration of acapatamab treatment was 98.43 weeks/AMG 404 treatment was 105.14 weeks)
|
|
Subprotocols A, B, C (Parts 1 and 2) and D: Percentage of Participants Who Experienced a PSA Response
Lasso di tempo: Cycle 1 Day 1 to 5 months post-last dose of acapatamab/AMG 404 (each cycle was 28 days, maximum duration of acapatamab treatment was 98.43 weeks/AMG 404 treatment was 105.14 weeks)
|
A PSA response was defined as the below and must have been confirmed by a second consecutive value 3 weeks later:
The baseline was defined as the last non-missing value on or prior to the pre-dose of acapatamab assessments on Cycle 1 Day 1. |
Cycle 1 Day 1 to 5 months post-last dose of acapatamab/AMG 404 (each cycle was 28 days, maximum duration of acapatamab treatment was 98.43 weeks/AMG 404 treatment was 105.14 weeks)
|
|
Subprotocols A, B, C (Parts 1, 2 and 3) and D: Duration of CTC0 Response
Lasso di tempo: From date of initial CTC0 response to the earlier of CTC0 progression or death (maximum duration of acapatamab treatment was 98.43 weeks/AMG 404 treatment was 105.14 weeks)
|
Duration of CTC0 response was defined as the time from the date of initial CTC0 response to the earlier of CTC0 progression or death.
Participants who had not ended their response at the time of analysis had duration of CTC0 response censored on the date of their last CTC0 or CTC conversion assessment.
|
From date of initial CTC0 response to the earlier of CTC0 progression or death (maximum duration of acapatamab treatment was 98.43 weeks/AMG 404 treatment was 105.14 weeks)
|
|
Subprotocols A, B, C (Parts 1, 2 and 3) and D: Duration of CTC Conversion Response
Lasso di tempo: From the date of an initial CTC conversion response to the earlier of CTC conversion progression or death (maximum duration of acapatamab treatment was 98.43 weeks/AMG 404 treatment was 105.14 weeks)
|
Duration of CTC conversion response was defined as the time from the date of an initial CTC conversion response to the earlier of CTC conversion progression or death.
Participants who had not ended their response at the time of analysis had duration of CTC response censored on the date of their last CTC0 or CTC conversion assessment.
|
From the date of an initial CTC conversion response to the earlier of CTC conversion progression or death (maximum duration of acapatamab treatment was 98.43 weeks/AMG 404 treatment was 105.14 weeks)
|
|
Subprotocols A, B, C (Parts 1, 2 and 3) and D: Duration of PSA Response
Lasso di tempo: From date of an initial PSA response (PSA 50) to the earlier of PSA progression or death (maximum duration of acapatamab treatment was 98.43 weeks/AMG 404 treatment was 105.14 weeks)
|
Duration of PSA response was defined as the time of an initial PSA response (PSA 50) to the earlier of PSA progression or death.
Participants who had not ended their response at the time of analysis had duration of PSA response censored on the date of their last PSA measurement.
|
From date of an initial PSA response (PSA 50) to the earlier of PSA progression or death (maximum duration of acapatamab treatment was 98.43 weeks/AMG 404 treatment was 105.14 weeks)
|
|
Subprotocols A, B, C (Parts 1, 2 and 3) and D: Duration of Response Per RECIST 1.1
Lasso di tempo: From date of an initial objective response per RECIST 1.1 to the earlier of soft-tissue progression per RECIST 1.1 or death (maximum duration of acapatamab treatment was 98.43 weeks/AMG 404 treatment was 105.14 weeks)
|
Duration of response per RECIST 1.1 was defined as the time from the date of an initial objective response (CR/PR) per RECIST 1.1 to the earlier of soft-tissue progression per RECIST 1.1 or death.
CR/PR must have been confirmed at least 4 weeks later.
Participants who had not ended their response at the time of analysis had duration of response censored at their last evaluable tumor assessment by computed tomography (CT)/magnetic resonance imaging (MRI) scan.
|
From date of an initial objective response per RECIST 1.1 to the earlier of soft-tissue progression per RECIST 1.1 or death (maximum duration of acapatamab treatment was 98.43 weeks/AMG 404 treatment was 105.14 weeks)
|
|
Subprotocols A, B, C (Parts 1, 2 and 3) and D: Overall Survival (OS)
Lasso di tempo: From the date of study Day 1 until death due to any cause (maximum duration of acapatamab treatment was 98.43 weeks/AMG 404 treatment was 105.14 weeks)
|
OS was defined as the time from the date of trial Day 1 until death due to any cause.
OS time (months) = (date of death - trial Day 1 + 1) x 12/365.25.
Any participant not known to have died at the time of analysis was censored based on the last recorded date on which the participant was alive.
The median was estimated using the Kaplan-Meier method and the 95% confidence interval was estimated using the method by Kalbfleisch and Prentice.
|
From the date of study Day 1 until death due to any cause (maximum duration of acapatamab treatment was 98.43 weeks/AMG 404 treatment was 105.14 weeks)
|
|
Subprotocols A, B, C (Parts 1, 2 and 3) and D: Radiographic Progression Free Survival (rPFS)
Lasso di tempo: From trial Day 1 to the earlier of a radiographic progression or death from any cause (maximum duration of acapatamab treatment was 98.43 weeks/AMG 404 treatment was 105.14 weeks)
|
rPFS was defined as the time from trial Day 1 to radiographic progression.
If a participant had no evaluable post-baseline and on-trial disease assessment and was on trial without disease progression (PD) or death recorded, rPFS was censored on the date of the first dose of the investigational product (IP).
rPFS was censored at the last evaluable radiographic tumor assessment date for participants who had no PD, death or new anti-cancer therapy reported, started a new anti-cancer therapy prior to PD or death, if death recorded without new anti-cancer therapy and without PD, if death or PD immediately after more than one consecutively missed tumor assessment occurred.
The median was estimated using the Kaplan-Meier method and the 95% confidence interval was estimated using the method by Brookmeyer and Crowley.
|
From trial Day 1 to the earlier of a radiographic progression or death from any cause (maximum duration of acapatamab treatment was 98.43 weeks/AMG 404 treatment was 105.14 weeks)
|
|
Subprotocols A, B, C (Parts 1, 2 and 3) and D: PSA PFS
Lasso di tempo: From trial Day 1 to the earlier of a PSA progression or death from any cause (maximum duration of acapatamab treatment was 98.43 weeks/AMG 404 treatment was 105.14 weeks)
|
PSA PFS was defined as the interval from trial Day 1 to the earlier of a PSA progression or death from any cause; otherwise, PSA PFS was censored on the date of the last PSA measurement.
If a participant had no baseline or post-baseline PSA measurement and a vital status of alive or known, PSA PFS was censored at trial Day 1.
The median was estimated using the Kaplan-Meier method and the 95% confidence interval was estimated using the method by Brookmeyer and Crowley.
|
From trial Day 1 to the earlier of a PSA progression or death from any cause (maximum duration of acapatamab treatment was 98.43 weeks/AMG 404 treatment was 105.14 weeks)
|
|
Subprotocols A, B, C (Parts 1, 2 and 3) and D: Clinical PFS
Lasso di tempo: From first dose of acapatamab or AMG 404 (subprotocol C only) to clinical disease progression or death from any cause (maximum duration of acapatamab treatment was 98.43 weeks/AMG 404 treatment was 105.14 weeks)
|
Clinical PFS was defined as the time from the first dose to clinical disease progression or death from any cause.
If a participant had no evaluable post-baseline or on-trial disease assessment or was on trial without PD or death recorded, clinical PFS was censored on the date of the first dose of the IP.
Otherwise, clinical PFS was censored on the date of last assessment.
The median was estimated using the Kaplan-Meier method and the 95% confidence interval was estimated using the method by Brookmeyer and Crowley.
|
From first dose of acapatamab or AMG 404 (subprotocol C only) to clinical disease progression or death from any cause (maximum duration of acapatamab treatment was 98.43 weeks/AMG 404 treatment was 105.14 weeks)
|
|
Subprotocols A, B, C (Parts 1, 2 and 3) and D: Time to Radiographic Progression
Lasso di tempo: From trial Day 1 to radiographic progression in the absence of subsequent anticancer therapy (maximum duration of acapatamab treatment was 98.43 weeks/AMG 404 treatment was 105.14 weeks)
|
Time to radiographic progression was defined as the interval from Day 1 to radiographic progression in the absence of subsequent anticancer therapy. If a participant had no evaluable post-baseline and on-trial disease assessment and was on trial without PD or death recorded, time to radiographic progression was censored on the date of the first dose of the IP. Time to radiographic progression was censored on the date of last evaluable radiographic tumor assessment for participants who:
The median was estimated using the Kaplan-Meier method and the 95% CI was estimated using the method by Brookmeyer and Crowley. |
From trial Day 1 to radiographic progression in the absence of subsequent anticancer therapy (maximum duration of acapatamab treatment was 98.43 weeks/AMG 404 treatment was 105.14 weeks)
|
|
Subprotocols A, B, C (Parts 1, 2 and 3) and D: Time to PSA Progression
Lasso di tempo: From trial Day 1 to PSA progression (maximum duration of acapatamab treatment was 98.43 weeks/AMG 404 treatment was 105.14 weeks)
|
Time to PSA progression was defined as the interval from trial Day 1 to PSA progression.
If a participant had no evaluable post-baseline or on-trial PSA assessment, time to PSA progression was censored on the date of the first dose of the IP.
Otherwise, time to PSA progression was censored on the date of the last PSA assessment.
The median was estimated using the Kaplan-Meier method and the 95% confidence interval was estimated using the method by Brookmeyer and Crowley.
|
From trial Day 1 to PSA progression (maximum duration of acapatamab treatment was 98.43 weeks/AMG 404 treatment was 105.14 weeks)
|
|
Subprotocols A, B, C (Parts 1, 2 and 3) and D: Time to Subsequent Therapy
Lasso di tempo: From trial Day 1 to the time a participant starts/receives the subsequent cancer therapy/subsequent therapy (maximum duration of acapatamab treatment was 98.43 weeks/AMG 404 treatment was 105.14 weeks)
|
Time to subsequent therapy was defined as the interval from trial Day 1 to the time a participant starts/receives the subsequent cancer therapy/subsequent therapy; otherwise, time to subsequent therapy was censored at the last known date of any of the trial assessments prior to initiating the subsequent cancer therapy/subsequent therapy.
The median was estimated using the Kaplan-Meier method and the 95% confidence interval was estimated using the method by Brookmeyer and Crowley.
|
From trial Day 1 to the time a participant starts/receives the subsequent cancer therapy/subsequent therapy (maximum duration of acapatamab treatment was 98.43 weeks/AMG 404 treatment was 105.14 weeks)
|
|
Subprotocols A, B, C (Parts 1, 2 and 3) and D: Percentage of Participants Who Experienced a Gallium Prostate-specific Membrane Antigen-11 (PSMA-11) Response
Lasso di tempo: Cycle 1 Day 1 to 14 days post-last dose of acapatamab or AMG 404 (maximum duration of acapatamab treatment was 98.43 weeks/AMG 404 treatment was 105.14 weeks)
|
A Gallium PSMA-11 response was defined as a ≥ 50% reduction from baseline in the maximum standardized update value (SUV) using 68Gallium (68Ga)-PSMA-11 positron emission tomography (PET)/CT.
PSMA-11 response percentages were based on the number of participants with a baseline PSMA assessment (defined as the last non-missing value on or prior to the pre-dose of acapatamab/AMG 404 assessments) on Cycle 1 Day 1.
The 95% confidence interval was calculated based on the Clopper-Pearson method.
|
Cycle 1 Day 1 to 14 days post-last dose of acapatamab or AMG 404 (maximum duration of acapatamab treatment was 98.43 weeks/AMG 404 treatment was 105.14 weeks)
|
|
Subprotocols A, B, C (Parts 1, 2 and 3) and D: Time to Symptomatic Skeletal Events
Lasso di tempo: From trial Day 1 to the first symptomatic skeletal event (maximum duration of acapatamab treatment was 98.43 weeks/AMG 404 treatment was 105.14 weeks)
|
Time to symptomatic skeletal events was defined as time from trial Day 1 to the first symptomatic skeletal event, otherwise time to symptomatic skeletal event was censored at the last dose of acapatamab/AMG 404 or end of safety follow-up date, whichever was later.
Symptomatic skeletal events included fracture, spinal cord compression and radiation or surgery to bone.
The median was estimated using the Kaplan-Meier method and the 95% confidence interval was estimated using the method by Brookmeyer and Crowley.
|
From trial Day 1 to the first symptomatic skeletal event (maximum duration of acapatamab treatment was 98.43 weeks/AMG 404 treatment was 105.14 weeks)
|
|
Subprotocols A, B, C (Parts 1, 2 and 3) and D: Total Alkaline Phosphatase Levels
Lasso di tempo: Baseline and end of treatment visit (up to 14 days post-last dose of acapatamab/AMG 404. Each cycle was 28 days, maximum duration of acapatamab treatment was 98.43 weeks/AMG 404 treatment was 105.1 weeks).
|
Alkaline phosphatase levels were collected locally and centrally.
|
Baseline and end of treatment visit (up to 14 days post-last dose of acapatamab/AMG 404. Each cycle was 28 days, maximum duration of acapatamab treatment was 98.43 weeks/AMG 404 treatment was 105.1 weeks).
|
|
Subprotocols A, B, C (Parts 1, 2 and 3) and D: Bone Specific Alkaline Phosphatase Levels
Lasso di tempo: Baseline and end of treatment visit (up to 14 days post-last dose of acapatamab/AMG 404. Each cycle was 28 days, maximum duration of acapatamab treatment was 98.43 weeks/AMG 404 treatment was 105.1 weeks).
|
Bone specific alkaline phosphatase levels were collected locally and centrally.
|
Baseline and end of treatment visit (up to 14 days post-last dose of acapatamab/AMG 404. Each cycle was 28 days, maximum duration of acapatamab treatment was 98.43 weeks/AMG 404 treatment was 105.1 weeks).
|
|
Subprotocols A, B, C (Parts 1, 2 and 3) and D: Lactate Dehydrogenase Levels
Lasso di tempo: Baseline and end of treatment visit (up to 14 days post-last dose of acapatamab/AMG 404. Each cycle was 28 days, maximum duration of acapatamab treatment was 98.43 weeks/AMG 404 treatment was 105.1 weeks).
|
Lactate dehydrogenase levels were collected locally and centrally.
|
Baseline and end of treatment visit (up to 14 days post-last dose of acapatamab/AMG 404. Each cycle was 28 days, maximum duration of acapatamab treatment was 98.43 weeks/AMG 404 treatment was 105.1 weeks).
|
|
Subprotocols A, B, C (Parts 1, 2 and 3) and D: Hemoglobin Levels
Lasso di tempo: Baseline, safety follow-up visit (up to 30 days post-last dose of acapatamab/AMG 404), safety follow-up 2 (subprotocol C only, up to 5 months post-dose). Each cycle = 28 days, max acapatamab duration = 98.43 weeks, max AMG 404 duration = 105.1 weeks.
|
Hemoglobin levels were collected locally.
|
Baseline, safety follow-up visit (up to 30 days post-last dose of acapatamab/AMG 404), safety follow-up 2 (subprotocol C only, up to 5 months post-dose). Each cycle = 28 days, max acapatamab duration = 98.43 weeks, max AMG 404 duration = 105.1 weeks.
|
|
Subprotocols A, B, C (Parts 1, 2 and 3) and D: Neutrophil-to-lymphocyte Ratio
Lasso di tempo: Baseline, safety follow-up visit (up to 30 days post-last dose of acapatamab/AMG 404), safety follow-up 2 (subprotocol C only, up to 5 months post-dose). Each cycle = 28 days, max acapatamab duration = 98.43 weeks, max AMG 404 duration = 105.1 weeks.
|
Data for the neutrophil-to-lymphocyte ratio were collected locally.
Neutrophil-to-lymphocyte ratio was calculated by dividing the number of absolute neutrophils by the number of lymphocytes.
|
Baseline, safety follow-up visit (up to 30 days post-last dose of acapatamab/AMG 404), safety follow-up 2 (subprotocol C only, up to 5 months post-dose). Each cycle = 28 days, max acapatamab duration = 98.43 weeks, max AMG 404 duration = 105.1 weeks.
|
|
Subprotocols A, B, C (Parts 1, 2 and 3) and D: Urine N-telopeptide Levels
Lasso di tempo: Baseline and end of treatment visit (up to 14 days post-last dose of acapatamab/AMG 404. Each cycle was 28 days, maximum duration of acapatamab treatment was 98.43 weeks/AMG 404 treatment was 105.1 weeks).
|
Urine N-telopeptide levels were collected centrally.
|
Baseline and end of treatment visit (up to 14 days post-last dose of acapatamab/AMG 404. Each cycle was 28 days, maximum duration of acapatamab treatment was 98.43 weeks/AMG 404 treatment was 105.1 weeks).
|
|
Subprotocol A, B and C (Parts 1 and 2) and D: Maximum Serum Concentration (Cmax) of Acapatamab
Lasso di tempo: Cycle 1: Days 1 to 7 and Cycle 2: Days 1 to 14 (each cycle was 28 days)
|
Serum concentrations of acapatamab were determined using a validated assay.
|
Cycle 1: Days 1 to 7 and Cycle 2: Days 1 to 14 (each cycle was 28 days)
|
|
Subprotocol A, B and C (Parts 1 and 2) and D: Area Under the Curve Over the Dosing Interval (AUCtau)
Lasso di tempo: Cycle 1: Days 1 to 7 and Cycle 2: Days 1 to 14 (each cycle was 28 days)
|
Serum concentrations of acapatamab were determined using a validated assay.
|
Cycle 1: Days 1 to 7 and Cycle 2: Days 1 to 14 (each cycle was 28 days)
|
|
Subprotocol A, B and C (Parts 1 and 2) and D: Time to Reach Cmax (Tmax) of Acapatamab
Lasso di tempo: Cycle 1: Days 1 to 7 and Cycle 2: Days 1 to 14 (each cycle was 28 days)
|
Serum concentrations of acapatamab were determined using a validated assay.
|
Cycle 1: Days 1 to 7 and Cycle 2: Days 1 to 14 (each cycle was 28 days)
|
|
Subprotocol A, B and C (Parts 1 and 2) and D: Terminal Half-life (t1/2z) of Acapatamab
Lasso di tempo: Cycle 2: Days 1 to 14 (each cycle was 28 days)
|
Serum concentrations of acapatamab were determined using a validated assay.
|
Cycle 2: Days 1 to 14 (each cycle was 28 days)
|
|
Subprotocol C, Part 3: Number of Participants Who Experienced TEAEs and Treatment-related AEs
Lasso di tempo: From first dose of AMG 404 to the first of 30 days after last dose of acapatamab, end of trial date or the initiation of a new anticancer therapy; median (min, max) duration was 6.14 (0.14, 105.14) weeks
|
A TEAE was defined as any untoward medical occurrence in a clinical trial participant irrespective of a causal relationship with the trial treatment that started after the first dose of acapatamab. A treatment-related TEAE was defined as a TEAE that had a reasonable possibility of being caused by acapatamab. Clinically significant changes from baseline in vital signs and clinical laboratory tests were also recorded as TEAEs. |
From first dose of AMG 404 to the first of 30 days after last dose of acapatamab, end of trial date or the initiation of a new anticancer therapy; median (min, max) duration was 6.14 (0.14, 105.14) weeks
|
Collaboratori e investigatori
Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.
Sponsor
Sponsor
Investigatori
Investigatori
- Direttore dello studio: MD, Amgen
Pubblicazioni e link utili
La persona responsabile dell'inserimento delle informazioni sullo studio fornisce volontariamente queste pubblicazioni. Questi possono riguardare qualsiasi cosa relativa allo studio.
Collegamenti utili
Studiare le date dei record
Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.
Studia le date principali
Inizio studio (Effettivo)
Inizio studio
15 gennaio 2021
Completamento primario (Effettivo)
Completamento primario
23 ottobre 2023
Completamento dello studio (Effettivo)
Completamento dello studio
23 ottobre 2023
Date di iscrizione allo studio
Primo inviato
Primo inviato
13 novembre 2020
Primo inviato che soddisfa i criteri di controllo qualità
Primo inviato che soddisfa i criteri di controllo qualità
13 novembre 2020
Primo Inserito (Effettivo)
Primo Inserito
17 novembre 2020
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento pubblicato
26 agosto 2026
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo aggiornamento inviato che soddisfa i criteri QC
4 agosto 2026
Ultimo verificato
Ultimo verificato
1 luglio 2026
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
- mCRPC
- Acapatamab
- MORSO ESTESO DI EMIVITA (HLE).
- Cancro alla prostata metastatico resistente alla castrazione
- 68
- Gallio (68Ga)-membrana specifica per la prostata
- antigene (PSMA)-11 emissione di positroni
- tomografia (PET)/tomografia computerizzata (TC)
- E
- 18
- F-fluorodesossiglucosio (FDG) PET/CT
- valutazione della risposta basata
- Attivatore di cellule T bispecifiche
- MORSO
Termini MeSH pertinenti aggiuntivi
- Ferite e lesioni
- Disturbi indotti chimicamente
- Avvelenamento
- Morsi e punture
- Agenti antineoplastici, immunologici
- Agenti antineoplastici
- Effetti fisiologici dei farmaci
- Meccanismi molecolari dell'azione farmacologica
- Ormoni, sostituti ormonali e antagonisti ormonali
- Antagonisti ormonali
- Antagonisti degli androgeni
- Aminoacidi, peptidi e proteine
- Proteine
- Azioni farmacologiche
- Azioni e usi chimici
- Usi terapeutici
- Enzimi
- Enzimi e coenzimi
- Ossidoreduttasi
- Citocromi
- Oxygenasi di funzione mista
- Oxygenasi
- Hemeproteins
- Inibitori del checkpoint immunitario
- Antagonisti del recettore degli androgeni
- Abiraterone
- Enzalutamide
- Sistema enzimatico P-450 del citocromo
Altri numeri di identificazione dello studio
Altri numeri di identificazione dello studio
- 20190505
- 2020-001305-23 (Numero EudraCT)
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
SÌ
Descrizione del piano IPD
Dati dei singoli pazienti anonimizzati per le variabili necessarie per affrontare la domanda di ricerca specifica in una richiesta di condivisione dei dati approvata.
Periodo di condivisione IPD
Le richieste di condivisione dei dati relative a questo studio saranno prese in considerazione a partire da 18 mesi dopo la conclusione dello studio e se 1) il prodotto e l'indicazione hanno ottenuto l'autorizzazione all'immissione in commercio sia negli Stati Uniti che in Europa o 2) lo sviluppo clinico per il prodotto e/o l'indicazione viene interrotto e i dati non saranno presentati alle autorità di regolamentazione.
Non esiste una data di fine per l'idoneità a inviare una richiesta di condivisione dei dati per questo studio.
Criteri di accesso alla condivisione IPD
I ricercatori qualificati possono presentare una richiesta contenente gli obiettivi della ricerca, il/i prodotto/i Amgen e lo/gli studio/studi Amgen nell'ambito, gli endpoint/i risultati di interesse, il piano di analisi statistica, i requisiti in materia di dati, il piano di pubblicazione e le qualifiche del/i ricercatore/i.
In generale, Amgen non soddisfa le richieste esterne di dati dei singoli pazienti allo scopo di rivalutare i problemi di sicurezza ed efficacia già affrontati nell'etichettatura del prodotto.
Le richieste vengono esaminate da un comitato di consulenti interni.
In caso di mancata approvazione, un comitato di revisione indipendente sulla condivisione dei dati arbitrerà e prenderà la decisione finale.
Dopo l'approvazione, le informazioni necessarie per affrontare la domanda di ricerca saranno fornite secondo i termini di un accordo di condivisione dei dati.
Ciò può includere dati anonimizzati di singoli pazienti e/o documenti di supporto disponibili, contenenti frammenti di codice di analisi ove previsto nelle specifiche di analisi.
Ulteriori dettagli sono disponibili all'URL sottostante.
Tipo di informazioni di supporto alla condivisione IPD
- STUDIO_PROTOCOLLO
- LINFA
- ICF
- RSI
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Sì
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
No
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .